Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Lenvatinib
Related studies linked through entity extraction aliases.
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Status
- TERMINATED
- Phase
- PHASE1
Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- NA
Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)
- Status
- COMPLETED
- Phase
- PHASE3
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)
- Status
- COMPLETED
- Phase
- PHASE3
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)
- Status
- COMPLETED
- Phase
- PHASE3
HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC
- Status
- WITHDRAWN
- Phase
- PHASE2
Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
- Status
- COMPLETED
- Phase
- PHASE2
Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria
- Status
- WITHDRAWN
- Phase
- PHASE3
Lenvatinib Plus PD-1 Antibody for Unresectable ICC
- Status
- SUSPENDED
- Phase
- PHASE2
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)
- Status
- COMPLETED
- Phase
- PHASE2
Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria
- Status
- WITHDRAWN
- Phase
- PHASE2
HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC
- Status
- UNKNOWN
- Phase
- PHASE3
Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC
- Status
- WITHDRAWN
- Phase
- PHASE2
Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC
- Status
- WITHDRAWN
- Phase
- PHASE3
Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
- Status
- COMPLETED
- Phase
- PHASE3
A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- N/A
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
- Status
- TERMINATED
- Phase
- PHASE2